Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Por Lordick, F, Luber, B, Lorenzen, S, Hegewisch-Becker, S, Folprecht, G, Wöll, E, Decker, T, Endlicher, E, Röthling, N, Schuster, T, Keller, G, Fend, F, Peschel, C
Publicado em 2010

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials

Por Giatromanolaki, A, Koukourakis, M I, Sivridis, E, Gatter, K C, Trarbach, T, Folprecht, G, Shi, M M, Lebwohl, D, Jalava, T, Laurent, D, Meinhardt, G, Harris, A L
Publicado em 2012

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

Por Schultheis, B., Folprecht, G., Kuhlmann, J., Ehrenberg, R., Hacker, U. T., Köhne, C. H., Kornacker, M., Boix, O., Lettieri, J., Krauss, J., Fischer, R., Hamann, S., Strumberg, D., Mross, K. B.
Publicado em 2013

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

Por Huebner, G, Link, H, Kohne, C H, Stahl, M, Kretzschmar, A, Steinbach, S, Folprecht, G, Bernhard, H, Al-Batran, S E, Schoffski, P, Burkart, C, Kullmann, F, Otremba, B, Menges, M, Hoffmann, M, Kaiser, U, Aldaoud, A, Jahn, A
Publicado em 2009

Report from the OECI Oncology Days 2014

Por van Harten, WH, Stanta, G, Bussolati, G, Riegman, P, Hoefler, G, Becker, KF, Folprecht, G, Truini, M, Haybaeck, J, Buiga, R, Dono, M, Bagg, A, López Guerrero, JA, Zupo, S, Lemare, F, de Lorenzo, F, Goedbloed, N, Razavi, D, Lövey, J, Cadariu, PA, Rollandi, GA, Paparo, F, Pierotti, M, Ciuleanu, T, De Paoli, P, Weiner, G, Saghatchian, M, Lombardo, Claudio
Publicado no Ecancermedicalscience (2014)